Toward precision medicine in pediatric population using cytochrome P450 phenotyping approaches and physiologically based pharmacokinetic modeling

Pediatr Res. 2020 Feb;87(3):441-449. doi: 10.1038/s41390-019-0609-z. Epub 2019 Oct 10.

Abstract

The activity of drug-metabolizing enzymes (DME) shows high inter- and intra-individual variability. Genetic polymorphisms, exposure to drugs, and environmental toxins are known to significantly alter DME expression. In addition, the activity of these enzymes is highly age-dependent due to maturation processes that occur during development. Currently, there is a vast choice of phenotyping methods in adults using exogenous probes to characterize the activity of these enzymes. However, this can hardly be applied to children since it requires the intake of non-therapeutic xenobiotics. In addition, sampling may be challenging in the pediatric population for a variety of reasons: limited volume (e.g., blood), inappropriate sampling methods for age (e.g., urine), and metric requiring invasive or multiple blood samples. This review covers the main existing methods that can be used in the pediatric population to determine DME activity, with a particular focus on cytochrome P450 enzymes. Less invasive tools are described, including phenotyping using endogenous probes. Finally, the potential of pediatric model-informed precision dosing using physiologically based pharmacokinetic modeling is discussed.

Publication types

  • Review

MeSH terms

  • Age Factors
  • Biological Variation, Individual
  • Biological Variation, Population
  • Cytochrome P-450 Enzyme System / genetics
  • Cytochrome P-450 Enzyme System / metabolism*
  • Drug Dosage Calculations
  • Genotype
  • Humans
  • Isoenzymes
  • Models, Biological*
  • Pediatrics*
  • Pharmacogenetics
  • Pharmacogenomic Variants
  • Pharmacokinetics*
  • Phenotype
  • Precision Medicine*
  • Substrate Specificity

Substances

  • Isoenzymes
  • Cytochrome P-450 Enzyme System